Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
- Sponsor
- Ondokuz Mayıs University
- Study ID
- NCT07535242
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Not accepted
Study Details
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Key Dates
- First listed
- Apr 17, 2026
- Start date
- Apr 21, 2026
- Status verified
- Apr 2026
- Primary completion
- Apr 30, 2026
- Completion
- May 5, 2026
Study Design
- Enrollment
- 22 participants (estimated)
Arms
- Arm: Progressive Multiple Sclerosis
Primary Outcome Measure
Expanded Disability Status Scale (EDSS) [ Time Frame: Baseline ]
Central Contacts
- Seda Nur Kemer+903623121919
Find similar trials
Related Studies
- Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Serum Auto-Antibodies in Neurological DiseasesEnrolling By Invitation · University of California, Davis · Sacramento, California
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- NARCOMS Registry: A Multiple Sclerosis RegistryRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas